137 related articles for article (PubMed ID: 22862168)
1. Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1.
Fan P; Zhang S; Tian H; Yan N; Dai L; Zhang X; Cheng L; Li C; Li Y; Chen X; Shi G; Yang Y; Wei Y; Deng H
Neoplasma; 2012; 59(6):676-84. PubMed ID: 22862168
[TBL] [Abstract][Full Text] [Related]
2. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
3. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
4. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.
Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G
Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
6. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
[TBL] [Abstract][Full Text] [Related]
8. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
9. PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.
Inoue M; Yoshimura M; Kobayashi M; Morinibu A; Itasaka S; Hiraoka M; Harada H
Sci Rep; 2015 Oct; 5():15666. PubMed ID: 26503893
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
Zhang Z; Zhang G; Kong C
J Cell Mol Med; 2017 Apr; 21(4):758-767. PubMed ID: 27878946
[TBL] [Abstract][Full Text] [Related]
11. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
12. Tumor inhibition by genomically integrated inducible RNAi-cassettes.
Kappel S; Matthess Y; Zimmer B; Kaufmann M; Strebhardt K
Nucleic Acids Res; 2006; 34(16):4527-36. PubMed ID: 16945954
[TBL] [Abstract][Full Text] [Related]
13. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
14. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
[TBL] [Abstract][Full Text] [Related]
15. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
Zhao XY; Nie CL; Liang SF; Yuan Z; Deng HX; Wei YQ
Biomed Pharmacother; 2012 Dec; 66(8):597-602. PubMed ID: 23153503
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase1 (Plk1) knockdown enhances cisplatin chemosensitivity via up-regulation of p73α in p53 mutant human epidermoid squamous carcinoma cells.
Tyagi S; Bhui K; Singh R; Singh M; Raisuddin S; Shukla Y
Biochem Pharmacol; 2010 Nov; 80(9):1326-34. PubMed ID: 20655883
[TBL] [Abstract][Full Text] [Related]
17. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells.
Chen Z; Chai Y; Zhao T; Li P; Zhao L; He F; Lang Y; Qin J; Ju H
J Cell Physiol; 2019 May; 234(5):5904-5914. PubMed ID: 30488440
[TBL] [Abstract][Full Text] [Related]
18. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]